Skip to main content
. 2021 Aug 26;12:735014. doi: 10.3389/fimmu.2021.735014

Figure 2.

Figure 2

AS1517499 attenuates myeloid fibroblast accumulation and macrophage polarization in the kidney with obstructive injury. (A) Representative photomicrographs of kidney sections at day 10 of UUO stained for CD45 (red), PDGFR-β (green), and DAPI (blue). Scale bar, 50μm. (B) Quantitative analysis of CD45+ and PDGFR-β+ fibroblasts in the kidney. ***P < 0.001 vs Vehicle-CON; ## P < 0.01 vs Vehicle-UUO; ++ P < 0.01 vs AS-UUO. n = 6 per group. (C) Representative photomicrographs of the kidney at day 10 of UUO stained for CD206 (red), PDGFR-β (green), and DAPI (blue). Scale bar, 50μm. (D) Quantitative analysis of CD206+ and PDGFR-β+ fibroblasts in the kidney. **P < 0.01 vs Vehicle-CON; ## P < 0.01 vs Vehicle-UUO; ++ P < 0.01 vs AS-UUO. n = 6 per group. (E) Quantitative analysis of mRNA expression of M2 macrophage makers (MRC, FIZZ1, Arg1, CCL17 in the kidney of Vehicle or AS1517499 treated mice. ***P < 0.001, **P < 0.01, *P < 0.05 vs Vehicle-CON; ## P < 0.01, # P < 0.05 vs Vehicle-UUO; +++ P < 0.001, + P < 0.05 vs AS-UUO. n = 6 per group.